Omninvest, German Diecon GmbH and Rommelag eye investments in Uzbek pharma market

9 February 2011

More and more Western pharmaceutical producers are considering establishing their production capacities in Uzbekistan, the former Soviet state, located in Central Asia.

For instance, Hungarian firm Omninvest Development KFT plans to invest $100 million in the construction of a plant for the production of vaccines and biological products in Uzbekistan. By mid-2012 the company aims to introduce the production of its diphtheria and tetanus toxoids and pertussis vaccines Calmette and Guerin, as well as typhoid- paratyphoid A and B vaccine (TAB) vaccines at the new plant.

In addition to Omninvest, German company Diecon GmbH is ready to invest over $150 million to establish a factory for the production of insulin, injections and other drugs in the Tashkent region of Uzbekistan, which will have a design capacity of 25 million single-dose in cartridges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK